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Abstract
The long-term exposure of doxorubicin (Dox) causes enhancement in MDR1 expression that leads to 
breast cancer cell resistance. This protein become a serious problem in cancer treatment and also well-known 
as negative prognostic factor in breast cancer malignancies. The new approach using natural chemopreventive 
substance was developed to inhibit this resistance progress. This study was aimed to investigate whether ethyl 
acetate fraction of Gynura procumnens (FEG) can prevent chemoresistance through suppressing the MDR1 protein 
expression.  MCF-7 cell was used as chemoresistance cell model. The MCF-7 cells were maintained with 100 
nM Dox-contained medium for fi ve weeks. The chemoprevention effect of FEG was investigated by treated 
MCF-7/Dox with sub-toxic concentration of  FEG. The cytotoxic properties of MCF-7 cells were determined 
using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) assay. Immunofl uorescence 
and western blotting analysis was performed to detect the MDR1 expression. MCF-7/Dox cells need higher 
concentration for inhibiting cell growth, were compared with MCF-7, shown by IC50 value. The MDR1 protein 
level elevated after Dox exposure in time dependent manner. The FEG treatment decreased MDR-1 protein 
level with dose dependent manner. FEG in combination with DOX potentiates the DOX effect on breast cancer 
cell growth inhibition. The FEG prevents the chemoresistance development in breast cancer cell line, MCF-7 
induced by Dox through inhibiting MDR1 expression. The additional of FEG enhances Dox effect on cell death 
induction. Thus, FEG could be developed as co-chemotherapy agent for reverse multidrug resistance.
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Introduction
Drug resistance becomes a major obstacle 
to the successful of cancer chemotherapy. 
There are several mechanisms mediate 
the drug resistance mechanism including 
drug inactivation, drug effl ux, drug target 
mutation, and the failure of apoptosis 
inisitian (Davis et al., 2003; Notarbartolo et 
al., 2005). Over expression of drug transporter 
such as P-gp plays a major role in causing 
multi drug resistance. P-gp is an adenosine 
triphosphatase (ATPase), a member of ATP-
binding cassette (ABC) transporter encoded 
by MDR1 gene. In normal cells, P-gp licalized 
at ephitel cell and has a functioan to eliminate 
xenobiotic and metabolit endogen. However, 
in some human cancers P-gp overexpression 
has high corelation with the decreasing 
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survival and become poor prognosis on 
cancer development (Leonessa and Clarke, 
2003). There is positive corelation between 
overall MDR1 expression and grade of 
breast cancer tumor (Surowiak et al., 2005). 
This protein become a serious problem in 
cancer treatment and also well-known as 
negative prognostic factor in breast cancer 
malignancies.
P-gp substrates include substances 
in variable structure, chemical properties 
and drug mechanism. Several cancer 
chemotherapy drugs such as anthracyclines, 
taxanes, and  epipodhophylotoxins already 
well-known as the substrate of this protein. 
Long time exposure of these agents on cancer 
cells triggers the transcriptional activity of 
MDR1 lead the increasing of P-gp (Germann, 
1996; Nielsen et al., 1996). The elevation of 
P-gp protein leads to chemotherapy failure 
due to cell resistance at several type of cancer. 
Doxorubicin which belongs to anthracyclin 
group could induce breast cancer multi drug 
resistance after long time exposure. DOX 
treatment increase P-gp expression level 
through Ras/Raf1 activation (Davis et al., 
2003). P-gp-mediated drug effl ux decreases 
intracellular Dox uptake and decrease its 
effi cacy. 
The development of P-gp inhibitors led 
to the third generation. Unfortunately, most 
of P-gp inhibitors that have been developed 
giving disappointing results. New approach 
using natural substances with moderate or 
low cytotoxic properties become a promising 
hope for reversing multi drug resistance 
due to MDR1 over expression. Natural 
fl avonoids have antitumor properties and 
others pharmacological activities related 
with its antitumor such as anti-infl ammatory 
and antioxidant. Flavonoid, especially 
flavones and flavonol show modulation 
effect on cancer cell growth through cell cycle 
arrest and apoptosis induction (Limtrakul et 
al., 2007). Quercetin and kaempferol down 
regulate multidrug resistance gene on human 
erythroleukemic K562/A cells. It causes 
decreasing of cells sensitivity to adriamycin 
(Yanqiu et al., 2011). Quercetin sensitizes 
cell resistance to daunorubicin through 
suppression on MDR1 expression and P-gp 
activity at human pancreatic carcinoma 
(Borska et al., 2010). 
Gynura procumbens is commonly used 
as herbal medicines in South-East Asia, 
especially Indonesia, Malaysia, and Thailand. 
The extract and fraction of this plant have high 
anti-infl ammatory and antioxidant properties 
(Iskander et al., 2002; Rosidah et al., 2008). The 
ethyl acetate fraction of G. procumbens (FEG) 
may contain quercetin and kaempferol. 
FEG sensitizes MCF-7 breast cancer cells 
to Doxorubicin treatment led to cell death. 
FEG modulates the microtubule integrity 
followed by cell cycle arrest and cell growth 
inhibition (Nurulita et al., 2012). In this study, 
we subject FEG to doxorubicin-resistance 
cell. We use MCF-7 cells treated by 100 nM 
doxorubicin for fi ve week as a model of cell 
resistance. We investigate the modulation on 
their sensitivity to doxorubicin, P-gp level, 
and cell growth. 
Materials and Methods
Plant material
The leaves of G. Procumbens were 
obtained from Balai  Penel i t ian dan 
Pengembangan Tanaman Obat dan Obat 
Tradisional (BP2TO2T) Indonesia. Dried 
powdered leaves were fi rst extracted with 
ethanol 96%, and concentrated by evaporation 
under reduced pressure and the temperature 
was kept below 40oC. The extract was diluted 
in hot water and then fractionated with 
n-hexane. The aqueous fraction then was 
fractionated again with ethyl acetate. The 
ethyl acetate fraction was concentrated by 
evaporation under reduced pressure and 
the temperature was kept below 40oC. The 
extract was stored at 4oC until used. 
Cells and chemicals
MCF-7 cells were obtained from 
Laboratorium of Gene Function in Animal, 
Nara Institute of Science and Technology 
(NAIST), Japan. MCF-7/DOX cells were 
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developed from MCF-7 cell that induced with 
100 nM DOX for fi ve weeks. The resistance 
development was checked by P-gp levels. The 
MCF-7 cells were routinely growed in DMEM 
(Nacalay Tesque) supplemented with 10% 
FBS (PAA Laboratories), 1% v/v Penicillin-
streptomycin (Sigma), and 1 mM L-glutamine 
(Nacalay Tesque)  at 37 oC in 5% CO2.  MCF-7/
DOX cells were maintained in 25 nM DOX-
contained medium. Doxorubicin (DOX) and 
5-Fluorouracil (5-FU) (Ebewe) was purchased 
from PT. Ferron Par Pharmaceutical Cikarang, 
Indonesia, Dimethyl sulfoxide (DMSO) 
(Sigma, Aldrich, Germany), penicillin and 
streptomycin (Gibco), Tripsin (Sigma), 3-(4,5-
dimethyltiazol-2-il)-2,5-diphenyltetrazolium 
bromide (MTT) (Sigma), triton X-100, 
4’,6-diamidino-2-phenylindole (DAPI) 
(Invitrogen) are at analytical degree.
Antibodies
Primary antibodies that used in western 
blotting and immunostaining were anti 
P-Glycoprotein (JSB-1) (GeneTex, Inc.), anti 
α-Tubulin (Santa Cruz), and secondary 
antibodies were diluted in PBS containing 
5% skim milk, 0,05% Tween (blocking buffer). 
For P-gp detection, the anti-P-gp and its 
secondary antibody were diluted in Can Get 
Signal (CGS) solution (Cosmo Bio). 
Cells growth assay 
Cells (104 cells/well) were seeded in 
96-well plate (100 μl/well). After 24 h of 
incubation, the medium was replaced with 
DOX, FEG, and its combination-containing 
medium. The medium was discarded and 
replaced with MTT-containing medium (0.5 
mg/ml) after 24 h incubation and incubated 
again for further 4 h at 37oC, 5% CO2. The 
reaction was stopped using 10%SDS  in 0.1 N 
HCl solution and was incubated for overnight 
in light protected chamber, to dissolve formasan 
salt. The absorbance of each well was measured 
by ELISA reader at 595 nm. The ratio between 
treated and control cells absorbance referred to 
percentage (%) of cells viability.
Gel electrophoresis and immunoblotting 
Cells were recovered, washed in PBS, 
and lysed for 30 min on ice using lysis buffer 
(20 mM Tris-HCl, pH 8, 0.5 mM EDTA, 1% 
NP40, 25 mM NaCl, and complete inhibitors 
of protease. Cells extract were centrifuged 
at 15.000 rpm for 20 min at 4oC to separate 
insoluble material. The protein concentration 
was determined using Bradford assay. Equal 
amount of each sample were mixed with SDS 
loading buffer, boiled for 3 min and subjected 
to SDS-PAGE at 120 V followed by electro 
blotting to Polyvinylidene fl uoride (PVDF) 
membranes for 2 h at 100 V. Membranes 
were blocked using 5% skim milk in PBS at 
room temperature for 1 hand subsequently 
probed with the primary antibody of interest. 
Blots were exposed by Chemilumi-oneSuper 
(Nacalay Tesque). 
Results
Long treatment of sub toxic concentration of 
DOX induced resistance cells development. 
Breast cancer cells become less sensitive 
to chemotherapy agen during the cells 
resistance development. After five weeks 
induced by DOX, MCF-7 cells decreased its 
sensitivity to DOX treatment, as shown by 
IC50 value (Table 1). 
Table 1. IC50 value of DOX and FEG on MCF-7 and 
MCF-7/DOX cells
Sample Cell Line IC50 value *
DOX MCF-7 410 ± 44       nM
MCF-7/Dox 921 ± 40       nM
FEG MCF-7 259 ± 29  μg/ml
MCF-7/Dox 161 ± 40  μg/ml
*average from two independent experiments
DOX resulted cell growth inhibition more 
than 2-fold higher  on MCF-7/DOX sub line 
than that of MCF-7 cell line (Figure 1A). FEG 
treatment showed the opposite results. FEG 
caused cell growth inhibition stronger on 
MCF-7/DOX sub line compared with MCF-7 
cell (Figure 1B). 
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DOX induced the elevation of P-gp level
DOX-induced MCF-7 cells showed the 
elevation of P-gp expression level in time 
dependent manner (Figure 2A). expression 
level of this protein was correlated with less 
sensitivity of MCF-7/DOX cells to DOX. 
FEG treatment decreased P-gp level in dose 
dependent pattern (Figure 2B). To make 
confirmation of this phenomenon, both 
immunobloting and immunofluorescence 
were conducted. FEG  decreased the green 
fl uorescence intensity that refer P-gp protein 
decreasing (Figure 3). DOX induces breast 
cancer cell resistance due to increasing of 
P-gp expression level. The P-gp protein 
has 170 kDa molecule size. This protein 
is hyperglycosilated as such appears as a 
diffuse band on Western blot results (Patel 
et al., 2002). We also found the additional 
band  below  P-gp protein size (Figure 2). The 
lower molecules weight bands was detected 
using the JSB-1 antibody for P-gp represent 
degraded product of P-gp protein. JSB-1 
antibody recognizes a cytoplasmic epitope 
of P-gp and does not cross-react with other 
protein such as MDR3 or muscle myosin, 
as does the C219 antibody (Leonessa and 
Clarke, 2003). 
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Figure 1. MCF-7/DOX cells are less sensitive to DOX (A) but more sensitive to FEG (B). Cells 
(104 cells/well) were cultured at 96-well plate, then treated with indicated concentration of 
DOX or FEG for 24 h incubation. Cells Viability was determined with MTT assay. This result 
represents from 3 independent experiments. The data was statistically analized by two tailed-
T-test analysis with p < 0,05.
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FEG reversed cell resistance and increased 
the sensitivity of MCF-7/DOX cells to DOX 
treatment
To investigate whether FEG could 
reverse the cell resistance development on 
MCF-7/DOX, MCF-7 cells were treated with 
DOX, FEG, or its combination and observed 
FEG reversal effect and its modulation 
on cell growth. Combination treatment of 
DOX+FEG suppressed cell growth o both of 
MCF-7 and MCF-7/DOX cells. The inhibition 
effect of combination treatment on MCF-7/
DOX cells more signifi cance compared to 
MCF-7 cells (Figure 4).
Discussion
P-glycoprotein (P-gp), a protein encoded 
by MDR-1 gene, has important function as 
ATP-dependent pump of drug effl ux. P-gp 
has specifi c substrate, such as vinca alkaloids, 
anthrasiclin, epipodhophylotoxins, and 
rhodamine. The exposure of These substrate 
to cancer cells could trigger transcriptional 
activity of MDR-1 (Germann, 1996; Lampidis 
et al., 1989; Nielsen et al., 1996). 
Previous study have found the long 
time exposure of DOX induced cancer cells 
resistance through the increasing level of 
P-gp (Abolhoda et al., 1999). In this study 
MCF-7 cells were used as resistance model 
of breast cancer. This cells were developed 
by long term sub toxic concentration of 
DOX induction. MCF-7 cells are cell line that 
express MDR1 and  Breast cancer resistance 
protein (BCRP) that will be triggered its 
expression after several chemotherapy 
agent induction (Faneyte et al., 2002). MDR-1 
expression elevates at patient after long time 
chemotherapy agent administration and had 
strong correlation with cancer chemotherapy 
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Figure 2. DOX induced P-gp expression on pada MCF-7 cells (A) and FEG prevents the elevation of 
this protein expression (B). Cells (106  cells/well) were seeded at 6-well plate, then treated with DOX, 
FEG or its combination for 24 h. Cell lysate then analyzed with Western blotting. Anti-α-tubulin 
was used for loading control. Dox1, Dox2, Dox3, and Dox4 refer to induction time for 2, 3, 4, and 5 
weeks, respectively. 
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Figure 3. DOX induced P-gp expression on pada MCF-7 cells and FEG prevents the elevation of this protein expression 
in concentration dependent manner. Cells (5.104   cells/well) were seeded on cover slip at 24-well plate. After treated 
with or without DOX+FEG for 24 h, then stained with anti-α-Tubulin (green fl uorescence) and counterstained with 
DAPI (blue fl uorescence). Cells were observed under fl uorescence microscope with 400x magnifi cation. 
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failure (Leonessa and Clarke, 2003).  This 
protein has identifi ed as negative prognostic 
in cancer diseases development. 
Sub toxic concentration of DOX for 
fi ve weeks decreased MCF-7 cells sensitivity 
to this agent, shown by IC50 value become 
more than 2 fold higher compared with 
MCF-7 cells. DOX exposure to MCF-7 cells 
lead to increasing expression of P-gp in 
time dependent manner. MCF-7 cells after 
fi ve weeks DOX induction (MCF-7/DOX) 
shown the significance increasing of this 
protein level compared with MCF-7 cells. 
The P-gp level has strong correlation with 
the low sensitivity of MCF-7/DOX to DOX 
exposure. 
The attempts to overcome drug 
resistance mediated by MDR-1 activation 
and elevation of P-gp level were developed 
the P-gp inhibitors. The agent that could 
suppress P-gp expression will increase 
uptake of chemotherapy agent and may 
influence its clinical efficacy. Flavonoids 
could modulate the expression and activation 
of P-gp. There are several mechanisms 
mediate their effect: changing membrane cells 
permeability, suppressing P-gp expression, 
inhibition ATPase activity, and occupation 
substrate binding site at P-gp, then changes its 
conformation (Arora et al., 2000; Boumendjel 
et al., 2002; Drori et al., 1995).
Natural compounds such as fl avonoids 
and polyphenol have signifi cant biological 
properties related to multidrug resistance 
development on cancer cells. Biochanin A and 
sylimarin inhibit drug effl ux from the cells by 
P-gp pump, and produce synergistic effect 
when combined with DOX at MCF-7 and 
MDA435/LCC6. Both compound decreased 
IC50 value of daunomycin significantly at 
MCF-7/Adr cells (Zhang and Morris, 2003; 
Chung et al., 2005). (-)-Epigallocatechin 
(EGC), (-)-epicatechin gallate (ECG), dan 
(-)-epigallocatechin gallate (EGCG) increase 
daunomycin accumulation at P-gp over-
expressing cells,  KB-C2 (Kitagawa et al., 
Figure 4. FEG increased the sensitivity 
of MCF-7/DOX cells to DOX. Cells (104 
cells/well) were cultured at 96-well 
plate, then treated with indicated 
concentration of DOX, FEG and its 
combination for 24 hours incubation. 
Cells Viability was determined with 
MTT assay. This result represents 
from 2 independent experiments 
with similar results. The data was 
statistically analized by two tailed-T-
test analysis. *p = 0,1 and **p = 0,028.
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Figure 4. FEG increased the sensitivity of MCF-7/DOX cells to DOX. Cells (104 cells/well) 
were cultured at 96-well plate, then treated with indicated concentration of DOX, FEG 
and its combination for 24 h incubation. Cells Viability was determined with MTT assay. 
This result represents from 2 independent experiments with similar results. The data was 
statistically analized by two tailed-T-test analysis. *p = 0,1 and **p = 0,028.
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2004). Flavonoid and polyphenol have a 
promising properties to be developed as P-gp 
inhibitor to prevent cell resistance.
FEG treatment enhances DOX cytotoxicity 
signifi cantly at MCF-7/DOX cells, higher than 
the effect on MCF-7 cells.  The inhibition of 
cells growth exhibited synergistic effect of 
combination treatment DOX+FEG in dose 
dependent manner. FEG treatment decreases 
P-gp expression level at MCF-7/DOX cells 
linear to the given concentration. The ethyl 
acetate fraction of G. procumbens (FEG) was 
suggested  have fl avon and or fl avonol with 
hydroxyl group modifi ed to be metoksi at 3 
and 4’, and asetoksi at 7 posisition (Sugiyanto 
et al., 2003). The ethyl acetate fraction of G. 
procumbens (FEG) may contain quercetin and 
kaempferol (Nurulita et al., 2012). FEG may 
modulate MDR-1 expression through the same 
mechanism with quercetin and kaempferol.
Quercetin inhibits the members of 
MDR1 family, such as : P-gp, MRP, and BCRP, 
competitively (Cooray et al., 2004; Scambia et 
al., 1994; van Zanden et al., 2005). Kaempferol 
and quercetin decrease P-gp expression and 
its activity at MDR KB-V1 cells (Limtrakul 
et al., 2005). Quercetin and kaempferol 
prevent cell resistance development through 
down regulate multidrug resistance gene 
on human erythroleukemic K562/A cells. 
It reverses cells sensitivity to adriamycin 
(Yanqiu et al., 2011). Quercetin suppresses 
MDR1 expression and P-gp activity at human 
pancreatic carcinoma. The net influx of 
daunorubicin increases when given together 
with quercetin (Borska et al., 2010). One study 
on structure activity relationship concludes 
fl avonoid with –OH group at 5 dan 7, with 
maximal have three total hydroxyl groups, 
and have strong inhibition on P-gp activity. 
Double bond at C2 and 3 as shown at fl avon 
generates its planarity, lead to intercalate 
with hydrophobic amino acids residue 
of P-gp (Sheu et al., 2010). Quercetin and 
kaempferol modulate both of MDR-1 gene 
and P-gp protein level and also its activity 
that reverse multidrug resistance on many 
type of cancer cell lines.
This study found that FEG decrease P-gp 
expression level at MCF-7/DOX cells. This 
results were suggested to the decreasing P-gp 
expression that may affect on the increasing 
of DOX accumulation at cancer cells. In the 
next study, monitoring the net uptake of 
DOX during co-treatment of FEG should be 
considered. This effect may precede  through 
several possibility, such as suppression 
on transcriptional activity of MDR-1 gene, 
translation, or post translation. 
As the conclusion, FEG prevents MCF-7 
cells from developing resistance through 
down-regulating P-gp expression. FEG 
in combination with DOX potentiates the 
DOX effect on breast cancer cell growth 
inhibition. Thus, FEG could be developed 
as co-chemotherapy agent for reversing 
multidrug resistance.
Acknowledgement
This work was supported by Sandwich-
like program 2010/2011, managing by 
Directorate General of Higher Education 
Republic of Indonesia, 2010
References
Abolhoda, A., Wilson, A.E., Ross, H. Danenberg, 
P.V. Burt, M., and Scotto, K.W. 1999, Rapid 
activation of MDR1 gene expression in 
human metastatic sarcoma after in vivo 
exposure to doxorubicin, Clin. Cancer Res., 
5, 3352-3356
Arora, A. Byrem, T.M., Nair, M.G., and 
Strasburg, G.M. 2000, Modulation 
of liposomal membrane fluidity by 
flavonoids and isoflavonoids, Arch 
Biochem. Biophys., 373, 102-109.
Borska, S., Sopel, M., Chmielewska, M., Zabel, 
M., and Dziegiel, P. 2010, Quercetin as a 
potential modulator of P-glycoprotein 
expression and function in cells of 
human pancreatic carcinoma line 
resistant to daunorubicin, Molecules, 
15, 857-870.
Boumendjel, A., Di Pietro, A., Dumontet, C., 
and Barron, D. 2002, Recent advances 
in the discovery of flavonoids and 
I.J. Biotech.
59
Nurulita et al.
analogues with high affi nity binding to 
P-glycoprotein responsible for cancer 
cell multidrug resistance, Med. Res. Rev., 
22, 512-529.
Chung, S.Y., Sung, M.K.,  Kim, N.H.,  Jang, 
J.O.,  Go, E.J., and Lee, H.J. 2005, 
Inhibition of P-glycoprotein by natural 
product in human breast cancer cells, 
Arch. Pharm. Res., 28(7), 823-828
Cooray, H.C., Janvilisri, T., van Veen, 
H.W., Hladky, S.B., and Barrand, 
M.A. 2004, Interaction of the breast 
cancer resistance protein with plant 
polyphenols, Biochem. Biophys. Res. 
Comm., 317, 269–275
Davis, J.M., Navolanic, P.M., Weinstein-
Oppenheimer, C.R., Steelman, L.S., 
Wei H., Konopleva, M., Blagosklonny, 
M.V., and McCubrey, J.A. 2003, Raf-1 
and Bcl-2 induce distinct and common 
pathways that contribute to breast 
cancer drug resistance, Clin. Cancer Res., 
9, 1161-1170.
Drori, S., Eytan, G.D., and Assaraf, Y.G. 
1995, Potentiation of anticancer-drug 
Cytotoxicity by multidrug-resistance 
chemosensitizers involves alterations in 
membrane fl uidity leading to increased 
membrane permeability, Eur. J. Biochem., 
228, 1020-1029.
Faneyte, I.F. Kristel, P.M.P. Maliepaard, 
M .  S c h e f f e r ,  G . L . S c h e p e r , R . J . 
Schellens, J.H.M. and van de Vijver, 
2002, Expression of the breast cancer 
resistance protein in breast cancer, Clin.
Cancer Res., 8,1068-1074.
Germann, U.A. 1996, P-glycoprotein – mediator 
of multidrug resistance in tumor cells, 
Eur. J. Cancer. 32A, 927-944
Iskander ,  M.N. ,  Song ,  Y . ,  Coupar , 
I.M., and Jiratchariyakul,W. 2002, 
Antiinfl amatory screening of medicinal 
plant G. Procumbens, Plant Foods Hum. 
Nutr., 57, 233-244.
Kitagawa, S., Nabekura, T., and Kamiyama, 
S. 2004,  Inhibition of P-glycoprotein 
function by tea catechins in KB-C2 cells. 
J. Pharm. Pharmacol., 56, 1001-1005.
Leonessa, F. and Clarke, R. 2003, ATP 
binding cassette transporters and drug 
resistance in breast cancer, Endocr. Relat.
Cancer, 10, 43-73.
Lampidis, T.J.,  Castello, C.,del Giglio, A., 
Pressman, B.C.,Viallet, P., Trevorrow, 
K.W. ,Valet, G.K., Tapiero, H., and 
Savaraj, N. 1989, Relevance of the 
chemical charge of rhodamine dyes 
to multiple drug resistance, Biochem. 
Pharmacol., 38, 4267-4271.
Limtrakul, P., Khantamat, O., and Pintha, 
K. 2007, Inhibition of P-glycoprotein 
function and expression by kaempferol 
and quercetin. J. Chemother., 17,  86-95.
Nielsen, D.,  Maare, C. and Skovsgaard,T. 1996, 
Cellular resistance to anthracyclins, 
Gen. Pharmacol., 27, 251-255.
Notarbartolo, M., Poma, P., Perri, D., 
Dusonchet, L.,  Cervello, M., and 
Alessandro, N. 2005, Antitumor effects 
of curcumin, alone or in combination 
with cisplatin or doxorubicin, on human 
hepatic cancer cells. Analysis of their 
possible relationship to changes in NF-
кB activation levels and in IAP gene 
expression, Cancer Lett., 224, 53-65.
Nurulita, N.A., Meiyanto, E., Sugiyanto, 
Matsuda, E., and Kawaichi, M., 2012, 
Gynura procumbens modulates the 
microtubules integrity and enhances 
distinct mechanism on doxorubicin and 
5-fl urouracil-induced breast cancer cell 
death, Orient. Pharm. Exp. Med., DOI 
10.1007/s13596-012-0063-5.
Nurulita, N.A., Meiyanto, E., and Sugiyanto, 
2012, Selectivity of ethyl acetate fraction 
of Gynura procumbens on colon cancer 
and breast cancer, Indo. J. Cancer 
Chemoprev., 3(4)
Pattel, V.A., Dunn, M.J., and Sorokin, A. 2002. 
Regulation of MDR-1 (P-glycoprotein) 
by cyclogenase 2. J. Biol. Chem., 277(41), 
38915-38920.
Rosidah, Yam, M.F., Sadikun, A. and Asmawi, 
M.Z. 2008, Antioxidant potential of 
Gynura procumbens, Pharmaceutic. Biol., 
46, 616-625.
I.J. Biotech.
60
Nurulita et al.
Scambia, G., Ranelletti, F.O., Panici, P.B., De 
Vincenzo, R., Bonanno, G., Ferrandina,G., 
Piantelli, M., Bussa, S., Rumi, C., and 
Cianfriglia, M. 1994, Quercetin potentiates 
the effect of adriamycin in a multidrug-
resistant MCF-7 human breastcancer cell 
line: P-glycoprotein as a possible target, 
Cancer Chemother. Pharmacol., 34, 459-464.
Sheu, M.T., Liou, Y.B., Kao, Y.H., Lin, Y.K., 
and Ho,H.O. 2010, A quantitative 
structure –activity relationship for the 
modulation effects of flavonoids on 
P-glycoprotein-mediated transport, 
Chem. Pharm. Bull., 58(9), 1187-1194.
Surowiak, P., Materna, V., Matkowski, R., 
Szczuraszek, K., Kornafel, J., Wojnar, 
A., Pudelko, M., Dietel, M., Denkert, 
C., Zabel, M., and Lage, H. 2005.
Relationship between the expression 
of cyclooxigenase 2 and MDR1/P-
glycoprotein in invasive breast cancers 
and their prognostic signifi cance, Breast 
Cancer Res., 7, R862-R870.
Sugiyanto, B., Sudarto, Meiyanto, E., 
Nugroho, A.E., and Jenie, U.A. 2003, 
The anticarcinogenic activity of plants 
compounds, Indo. J. Pharm., 14(4), 216-
225.
Van Zanden, J. J., Wortelboer, H. M., Bijlsma, 
S., Punt, A., Usta, M., Bladeren, P.J., 
Rietjens, I.M., and Cnubben, N.H. 
2005, Quantitative structure activity 
relationship studies on the fl avonoid 
mediated inhibition of multidrug 
resistance proteins 1 and 2. Biochem. 
Pharmacol., 69, 699–708, 2005.
Yanqiu, H., Linjuan, C., Jin, W., Hongjun, H., 
Yongjin, S., Guobin, X., and Hanyun, 
R. 2011. The effect of quercetin and 
kaempferol on multidrug resistance 
and the expression of related genes in 
human erythroleukimia K562/A cells, 
African J. Biotech, 10(62), 13399-13406.
Zhang, S. and Morris, M.E. 2003, Effects 
of  the f lavonoids biochanin A, 
morin, phloretin, and silymarin on 
P-glycoprotein-mediated transport, 
J.Pharmacol. Exp. Ther., 304, 1258-1267.
